Viewing Study NCT04124458


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2026-03-02 @ 4:05 AM
Study NCT ID: NCT04124458
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-02-15
First Post: 2019-10-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Occipital Nerve RF Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation
Sponsor: Allevio Pain Management Clinic
Organization:

Study Overview

Official Title: A Comparison of Pain Control AND Quality of Life Improvement Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation: A Double-Blind Single Center Prospective Study
Status: NOT_YET_RECRUITING
Status Verified Date: 2022-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a randomized, double blind, single-center, clinical trial. The study will be conducted over a period of 6 months. The study will be conducted at the Allevio Pain Clinic, Toronto, Canada.
Detailed Description: During the first visit the investigator will assess potential subject's eligibility. Screening and recruitment, and randomization, and administer questionnaires will be performed by research coordinator. Study informed consent form (ICF) can be signed on the RF procedure day. If additional visits will be required to finalize the procedures related to the first visit they will be scheduled accordingly. After randomization the qualified participants will be scheduled for their bilateral Occipital RF or bilateral Occipital Block.

Participants will be asked to complete the follow-up questionnaires at baseline, 3 and 6 months. On their last study visit, participants will have an exit interview, in addition to completing study measures.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: